Global Perspectives in Early-Stage Lung Cancer in 2023

Early lung cancer-specific discussions on therapeutic advances and their application in clinical decision-making

December 15, 2023
Corey Langer MD Scientific Leader Faculty Chair Aptitude Health


Corey Langer, MD, FACP

University of Pennsylvania, Philadelphia, PA, USA

Faculty Members

Nasser Hanna, MD
Indiana University Health, Indianapolis, IN, USA

Andrew Haas, MD, PhD
Penn Medicine, Philadelphia, PA, USA

Jonathan Spicer, MD, PhD
McGill University, Montreal, QC, Canada

Lynette Sholl, MD
Brigham and Women’s Hospital, Boston, MA, USA

Charles Simone II, MD, FASTRO, FACRO
Memorial Sloan Kettering Cancer Center, New York, NY, USA

Solange Peters, MD, PhD
University Hospital of Lausanne, Switzerland

Enriqueta Felip, MD, PhD
Vall d’Hebron University, Barcelona, Spain

Sample Report

Start discovering the insights

View Report


  • Immunotherapy: Neoadjuvant, Adjuvant, or Perioperative?
  • Oncogene-Driven NSCLC: EGFR/ALK – Do These Approaches Complement or Replace Chemotherapy?
  • The Road Forward for Other Drivers and Targets in Resectable NSCLC
  • Predictive Markers: Who Needs More Therapy, Who Needs Less?

Purchase Report

Thank you for your interest in our insights.

Complete the form below to receive additional information.